免疫抑制治疗与乙型肝炎再激活风险：共识报告
Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.
作者信息
Aygen Bilgehan, Demir Ahmet Muzaffer, Gümüş Mahmut, Karabay Oğuz, Kaymakoğlu Sabahattin, Köksal Aydın Şeref, Köksal İftihar, Örmeci Necati, Tabak Fehmi
机构信息
Department of Infectious Diseases and Clinical Microbiology, Erciyes University School of Medicine, Kayseri, Turkey.
Division of Hematology, Department of Internal Diseases, Trakya University School of Medicine, Edirne, Turkey.
出版信息
Turk J Gastroenterol. 2018 May;29(3):259-269. doi: 10.5152/tjg.2018.18263.
Abstract
This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to an emergency risk of hepatitis B reactivation. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.
摘要
本共识报告包含了有关筛查以及必要时对因乙型肝炎再激活紧急风险而将接受免疫抑制治疗的患者在治疗前进行乙型肝炎随访、预防和治疗的专家意见与建议。为提高对免疫抑制患者中乙型肝炎再激活风险的认识，来自土耳其多个大学健康研究与培训中心的院士齐聚一堂，根据当前文献数据讨论了该主题的重要性、现状及问题，并提出了解决方案。
相似文献
1
Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.免疫抑制治疗与乙型肝炎再激活风险：共识报告
Turk J Gastroenterol. 2018 May;29(3):259-269. doi: 10.5152/tjg.2018.18263.
2
Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy.需要免疫抑制治疗的乙肝病毒（HBV）感染患者中HBV再激活的特征、预防及管理
J Infect Dis. 2017 Nov 16;216(suppl_8):S778-S784. doi: 10.1093/infdis/jix178.
3
[Management of hepatitis B virus reactivation during chemotherapy or immunosuppressive therapy].化疗或免疫抑制治疗期间乙肝病毒再激活的管理
Presse Med. 2008 Nov;37(11):1591-8. doi: 10.1016/j.lpm.2008.03.011. Epub 2008 Jun 13.
4
American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.美国胃肠病学会关于免疫抑制药物治疗期间预防和治疗乙型肝炎病毒再激活的技术审查
Gastroenterology. 2015 Jan;148(1):221-244.e3. doi: 10.1053/j.gastro.2014.10.038. Epub 2014 Oct 31.
5
American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.美国胃肠病学会关于免疫抑制药物治疗期间预防和治疗乙型肝炎病毒再激活的指南。
Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7. doi: 10.1053/j.gastro.2014.10.039. Epub 2014 Oct 31.
6
A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection.从真实临床实践看免疫抑制导致 HBV 再激活的病毒学表现和结局：死亡风险增加和由潜伏感染向慢性感染演变的证据。
J Viral Hepat. 2019 Jul;26(7):846-855. doi: 10.1111/jvh.13101. Epub 2019 May 14.
7
Hepatitis B Reactivation: The Controversies Continue.乙肝再激活：争议仍在继续。
Dig Dis. 2017;35(4):351-358. doi: 10.1159/000456587. Epub 2017 May 3.
8
[Hepatitis B virus management to prevent reactivation].[预防再激活的乙型肝炎病毒管理]
Nihon Rinsho. 2015 Dec;73 Suppl 9:443-7.
9
Reactivation of hepatitis B virus associated with chemotherapy and immunosuppressive agent.与化疗和免疫抑制剂相关的乙型肝炎病毒再激活
Acta Med Indones. 2013 Jan;45(1):61-6.
10
Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study.司库奇尤单抗治疗合并乙型或丙型肝炎的银屑病患者的安全性：一项多中心前瞻性队列研究。
Acta Derm Venereol. 2018 Oct 10;98(9):829-834. doi: 10.2340/00015555-2989.
引用本文的文献
1
Real-world effectiveness, safety and immunogenicity of ocrelizumab in turkish multiple sclerosis patients: a single-center experience for 4-year follow-up.奥瑞珠单抗在土耳其多发性硬化症患者中的真实世界疗效、安全性和免疫原性：4 年随访的单中心经验。
Acta Neurol Belg. 2024 Aug;124(4):1385-1391. doi: 10.1007/s13760-024-02572-3. Epub 2024 May 20.
2
Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.奥瑞珠单抗治疗多发性硬化症患者的乙型肝炎病毒再激活风险：来自土耳其的观察性研究。
J Neurol. 2024 Jul;271(7):4131-4137. doi: 10.1007/s00415-024-12333-0. Epub 2024 Apr 5.
3
Risk of Reactivation of Hepatitis B in Hepatitis B Surface Antigen-Negative and Hepatitis B Core Antigen Antibody Positive Patients Receiving Biologic Therapy.接受生物治疗的乙肝表面抗原阴性和乙肝核心抗原抗体阳性患者中乙肝再激活的风险
Turk J Gastroenterol. 2023 Mar;34(3):308-309. doi: 10.5152/tjg.2023.23070.
4
[Drugs and hepatitis B virus reactivation].[药物与乙型肝炎病毒再激活]
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2022 Jun 25;39(3):627-632. doi: 10.7507/1001-5515.202112003.
5
Risk of hepatitis B reactivation: From biologic therapies for psoriasis to immunosuppressive therapies for COVID-19 (Review).乙肝再激活风险：从银屑病生物治疗到新冠病毒病免疫抑制治疗（综述）
Exp Ther Med. 2022 Jun;23(6):385. doi: 10.3892/etm.2022.11312. Epub 2022 Apr 12.
6
Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment.炎症性肠病患者在免疫抑制治疗下的乙型肝炎病毒感染管理。
World J Gastroenterol. 2021 Jul 7;27(25):3762-3779. doi: 10.3748/wjg.v27.i25.3762.
7
Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection.抗 TNF 治疗期间乙型肝炎再激活的风险；既往乙型肝炎感染患者的评估。
Turk J Gastroenterol. 2020 Jul;31(7):522-528. doi: 10.5152/tjg.2020.19295.
8
Is there any evidence implying the use of a different criterion for protective anti-HBs titer after HBV vaccination in immunosuppressed patients?是否有证据表明在免疫抑制患者中，乙肝疫苗接种后保护性抗-HBs滴度采用了不同的标准？
Turk J Gastroenterol. 2020 Apr;31(4):346-347. doi: 10.5152/tjg.2020.19040.
9
Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.依鲁替尼治疗慢性淋巴细胞白血病患者过程中出现的乙型肝炎病毒再激活
Turk J Haematol. 2020 Aug 28;37(3):208-209. doi: 10.4274/tjh.galenos.2020.2019.0180. Epub 2020 Apr 6.
10
Moderate Risk of Hepatitis B Virus Reactivation in HBsAg/HBcAb Carriers Receiving Rituximab for Rheumatoid Arthritis.接受利妥昔单抗治疗类风湿关节炎的 HBsAg/抗 HBc 阳性者存在乙型肝炎病毒再激活的中度风险。
Sci Rep. 2020 Feb 12;10(1):2456. doi: 10.1038/s41598-020-59406-4.
本文引用的文献
1
Medical interventions associated with HBV reactivation: Common and less common.与乙肝病毒再激活相关的医学干预措施：常见与不常见的。
Clin Liver Dis (Hoboken). 2015 Mar 27;5(2):32-34. doi: 10.1002/cld.413. eCollection 2015 Feb.
2
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.EASL 2017 临床实践指南：乙型肝炎病毒感染管理。
J Hepatol. 2017 Aug;67(2):370-398. doi: 10.1016/j.jhep.2017.03.021. Epub 2017 Apr 18.
3
Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.与免疫抑制及生物调节剂治疗相关的乙型肝炎再激活：当前概念、管理策略及未来方向
Gastroenterology. 2017 May;152(6):1297-1309. doi: 10.1053/j.gastro.2017.02.009. Epub 2017 Feb 20.
4
Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.表面抗体在已治愈感染和血液系统恶性肿瘤患者乙肝再激活中的作用：一项荟萃分析。
Hepatology. 2017 Aug;66(2):379-388. doi: 10.1002/hep.29082. Epub 2017 Jun 22.
5
Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment.乙型肝炎病毒在接受全身抗肿瘤治疗的实体瘤患者中的再激活。
Ann Oncol. 2016 Dec;27(12):2172-2184. doi: 10.1093/annonc/mdw414. Epub 2016 Nov 1.
6
Prevention of Hepatitis B reactivation in the setting of immunosuppression.免疫抑制情况下乙肝再激活的预防。
Clin Mol Hepatol. 2016 Jun;22(2):219-37. doi: 10.3350/cmh.2016.0024. Epub 2016 Jun 13.
7
Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy.癌症化疗及其他免疫抑制药物治疗背景下的乙型肝炎病毒再激活
Clin Infect Dis. 2016 Jun 1;62 Suppl 4(Suppl 4):S306-13. doi: 10.1093/cid/ciw043.
8
Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations.免疫抑制患者中乙肝再激活的管理：当前推荐的最新进展。
World J Hepatol. 2016 Mar 18;8(8):385-94. doi: 10.4254/wjh.v8.i8.385.
9
A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: a single-institutional experience.拉米夫定与恩替卡韦预防异基因造血干细胞移植受者乙肝病毒再激活的比较：单中心经验
Bone Marrow Transplant. 2016 Apr;51(4):581-6. doi: 10.1038/bmt.2015.328. Epub 2016 Jan 11.
10
AASLD guidelines for treatment of chronic hepatitis B.美国肝病研究学会慢性乙型肝炎治疗指南。
Hepatology. 2016 Jan;63(1):261-83. doi: 10.1002/hep.28156. Epub 2015 Nov 13.
Zotero 插件